Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05087849 · ClinicalTrials.gov registry record · Phase 1
Intralesional HPV Vaccine for Condylomata
A Phase 1 study of Human Papilloma Virus and Warts, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT05087849: Completed Phase 1 study of Human Papilloma Virus and Warts, sponsored by University of California, San Francisco.
NCT05087849 is a Phase 1 study of Human Papilloma Virus and Warts that has completed, run by University of California, San Francisco. The registered enrollment target is 2 participants, below the 8,441-participant average among 39 other Human Papilloma Virus trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05087849, a Phase 1 study of Human Papilloma Virus and Warts, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will investigate whether injecting genital warts with small quantities of the Gardasil 9 vaccine has an effect on the warts.
Primary Outcome
Change in number of warts in genital area.
Conditions Studied
Interventions
- BIOLOGICAL nonavalent human papillomavirus vaccine
Study Locations (1)
California
- Zuckerberg San Francisco General Hospital - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-04-15 |
| Est. Completion | 2024-07-01 |
| Phase | Phase 1 |
What the finished NCT05087849 record still lists
NCT05087849 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 8,441-participant average among 39 other Human Papilloma Virus trials with a reported enrollment target (100% lower).
The record links to 5 conditions, with Human Papilloma Virus appearing as the primary indexed condition, and to 1 intervention - of which nonavalent human papillomavirus vaccine is the first listed.
NCT05087849 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05087849 about?
NCT05087849 is a clinical study titled "Intralesional HPV Vaccine for Condylomata". This study will investigate whether injecting genital warts with small quantities of the Gardasil 9 vaccine has an effect on the warts.
What is the current status of trial NCT05087849?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2022-04-15. Estimated completion is 2024-07-01.
What conditions does trial NCT05087849 study?
This clinical trial studies the following conditions: Human Papilloma Virus, Warts, Condylomata Acuminata, Warts, Genital, Condyloma.
What interventions are being tested in trial NCT05087849?
The interventions under investigation include: nonavalent human papillomavirus vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05087849?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05087849 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papilloma Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05087849's enrollment target sits among peer trials
2 40th of 39 the lowest of 39 other Human Papilloma Virus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Human Papilloma Virus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
RECRUITING · Phase 1
-
Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery
RECRUITING · Phase 1
-
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
COMPLETED · Phase 1
-
Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine
RECRUITING · NA
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI